HOTH - Hoth Therapeutics inks deal for treatment of multi-drug resistant bacterial lung infections shares up 15%

Hoth Therapeutics (HOTH) jumps 15% premarket in reaction to the announcement that its has entered into a Non-Exclusive Commercial Evaluation License Agreement with the U.S. Army Medical Research and Development Command for a new molecular entity ((NME)) developed by the Walter Reed Army Institute of Research that targets multiple bacterial pathogens.While this NME (to be developed under the identifier "HT-006") has the potential to treat many different types of bacterial infections, Hoth will initially target treatment of serious bacterial infections of the lung, such as hospital-acquired pneumonia ((HAP)) and ventilator-associated pneumonia ((VAP)).Hoth intends to pursue streamlined development opportunities under the FDA program which allows for the use of nonclinical animal studies to reduce clinical studies required for approval.Preclinical studies investigating HT-006 for various multi-drug resistant bacterial species are planned to start in Q1 2021.

For further details see:

Hoth Therapeutics inks deal for treatment of multi-drug resistant bacterial lung infections, shares up 15%